Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial

INTRODUCTION: Persons with type 1 diabetes require intensive insulin therapy to achieve glycaemic control, but side effects, including hypoglycaemia and weight gain, may reduce treatment compliance. We hypothesise that add-on treatment of the short-acting glucagon-like peptide-1 receptor agonist, ex...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open
Main Authors: Johansen, Nicklas Järvelä, Dejgaard, Thomas Fremming, Lund, Asger, Vilsbøll, Tina, Andersen, Henrik Ullits, Knop, Filip Krag
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2018
Assuntos:
Diabetes and Endocrinology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6042609/
https://ncbi.nlm.nih.gov/pubmed/29950475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-021861
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados